Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.68 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.60 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.49 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211244 | 0.95 | MAPK14 (0.62) | NPC1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3222814 | 0.91 | MAPK14 (0.58) | NPC1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3218291 | 0.89 | MAPK14 (0.56) | NPC1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2979351 | 0.82 | RAB9A (1.00) | NPC1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3217850 | 0.82 | USP30 (0.58) | NPC1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL5631549 | 0.81 | MAPK14 (1.00) | MAPK14HSPB1CYP2C9MAPK11 | |
| SCHEMBL3205630 | 0.81 | TSHR (0.55) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL31367847 | 0.81 | MAPK14 (0.74) | NPC1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3218355 | 0.81 | MAPK14 (0.74) | MEN1KMT2AMAPK14HSPB1CYP2C9 | |
| SCHEMBL3224598 | 0.80 | ALDH1A1 (0.51) | MEN1KMT2ARAB9ASMN1; SMN2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | NPC1 2916/4885MEN1 2335/4885KMT2A 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.